6/264 PRESENTATION OF FINANCIAL AND OTHER INFORMATION Currency All references in this prospectus to (i) “Euro,” “EUR,” or “€” are to the currency of the member states participating in the European Monetary Union, and (ii) “U.S. dollar,” “USD,” or “$” are to the currency of the United States. Our reporting currency is the Euro. For the convenience of the reader, this prospectus contains translations of certain Euro amounts into U.S. dollars at specified rates. Unless otherwise indicated, the U.S. dollar equivalent for information in Euros is based on the exchange rates, as defined in “Currencies and Exchange Rates.” Presentation of Financial Information In accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”), we prepare our consolidated financial statements on a historical cost basis, except for our securities, long term investment, Convertible Notes (as defined herein), and derivative financial instruments, which have been measured at fair value. The financial information included in this prospectus for the years ended December 31, 2013 and 2014 have been presented without the retrospective application of IFRS 15, Revenue from Contracts with Customers (“IFRS 15”) and may not be comparable to the years ended December 31, 2015, 2016, and 2017. Non­IFRS Financial Measures In this prospectus, we present certain financial measures that are not recognized by IFRS and that may not be permitted to appear on the face of IFRS­compliant financial statements or notes thereto. The non­IFRS financial measures used in this prospectus are EBITDA and Free Cash Flow. For a discussion of EBITDA and Free Cash Flow and a reconciliation of each to their most closely comparable IFRS measures, see “Summary Consolidated Financial and Other Data” and “Selected Historical Financial Information and Other Data.” Presentation of Ordinary Shares As of February 22, 2018, we had 176,976,280 ordinary shares outstanding. Except as otherwise indicated, the number of ordinary shares outstanding excludes (i) 14,095,254 ordinary shares issuable upon exercise of stock options outstanding as of February 22, 2018 at a weighted­average exercise price of $49.02 per ordinary share, (ii) 191,985 ordinary shares issuable upon the settlement of restricted stock units (“RSUs”) outstanding as of February 22, 2018, and (iii) 6,720,000 ordinary shares issuable upon the exercise of warrants outstanding as of February 22, 2018, at a weighted average exercise price of $59.92 per ordinary share. Further, unless otherwise indicated, all information in this prospectus reflects a 40­to­one share split of our ordinary shares, beneficiary certificates, and any other outstanding securities, which we expect to effectuate prior to the effectiveness of this Registration Statement (the “Share Split”). The purpose of the Share Split is to reduce the per share price of our ordinary shares to a more customary level for a newly listed company on the NYSE. Rounding Certain monetary amounts, percentages, and other figures included in this prospectus have been subject to rounding adjustments. Accordingly, figures shown as totals in certain tables may not be the arithmetic aggregation of the figures that precede them, and figures expressed as percentages in the text may not total 100% or, as applicable, when aggregated may not be the arithmetic aggregation of the percentages that precede them. iv